Dual HER2 Blockade

摘要

Although nearly doubling the response rates by the addition of a second anti-HER2 compound to the standard neoadjuvant treatment with trastuzumab (NeoALTTO [1], NeoSPHERE [2]), the interpretation of the adjuvant trials (ALTTO [3], APHINITY [4]) is more challenging. We asked experts from different countries around the world about their conclusions from that data. The discussion was performed under the assumption that the drug would be available in the respective countries.